[ET Net News Agency, 23 August 2024] Citi lowered the target price for Wuxi Bio (02269)
to HKD30 from HKD35 and maintained the "buy" rating.
The research house said it cuts revenue forecasts by 0%/3%/7% and net profits by
6%/11%/14% in FY24/25/26 respectively to factor in negative margin effect of new capacity
construction and increasing minority interest of profit from WuXi XDC. (rc)